ECP
OREX

Empyrean Capital Partners’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Empyrean Capital Partners’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-5,000
Closed -$282K – 61
2013
Q4 		$282K Buy
+5,000
New +$281K 0.01% 51

Other funds holding OREX

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Empyrean Capital Partners's OREX Position: Q1 2014 in Review

Empyrean Capital Partners sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2014, closing a stake of 5,000 shares — an estimated $282K sold.

Empyrean Capital Partners first reported a position in OREX in Q4 2013 and held it in 1 quarter. The position peaked at $282K in Q4 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q1 2014.

  • Empyrean Capital Partners reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Empyrean Capital Partners sold 5,000 Orexigen Therapeutics, Inc. shares in Q1 2014, an estimated $282K.
  • Empyrean Capital Partners first reported a position in Orexigen Therapeutics, Inc. in Q4 2013 and held it in 1 quarter.
  • Empyrean Capital Partners's Orexigen Therapeutics, Inc. position peaked at $282K in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2014.

Based on Empyrean Capital Partners's 13F filing for Q1 2014, filed 14 May 2014.